Polygenic Risk Score-Enhanced Risk Stratification of Coronary Artery Disease in Patients With Stable Chest Pain.


Journal

Circulation. Genomic and precision medicine
ISSN: 2574-8300
Titre abrégé: Circ Genom Precis Med
Pays: United States
ID NLM: 101714113

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 26 5 2021
medline: 15 2 2022
entrez: 25 5 2021
Statut: ppublish

Résumé

Polygenic risk scores (PRSs) are associated with coronary artery disease (CAD), but the clinical potential of using PRSs at the single-patient level for risk stratification has yet to be established. We investigated whether adding a PRS to clinical risk factors (CRFs) improves risk stratification in patients referred to coronary computed tomography angiography on a suspicion of obstructive CAD. In this prespecified diagnostic substudy of the Dan-NICAD trial (Danish study of Non-Invasive testing in Coronary Artery Disease), we included 1617 consecutive patients with stable chest symptoms and no history of CAD referred for coronary computed tomography angiography. CRFs used for risk stratification were age, sex, symptoms, prior or active smoking, antihypertensive treatment, lipid-lowering treatment, and diabetes. In addition, patients were genotyped, and their PRSs were calculated. All patients underwent coronary computed tomography angiography. Patients with a suspected ≥50% stenosis also underwent invasive coronary angiography with fractional flow reserve. A combined end point of obstructive CAD was defined as a visual invasive coronary angiography stenosis >90%, fractional flow reserve <0.80, or a quantitative coronary analysis stenosis >50% if fractional flow reserve measurements were not feasible. The PRS was associated with obstructive CAD independent of CRFs (adjusted odds ratio, 1.8 [95% CI, 1.5-2.2] per SD). The PRS had an area under the curve of 0.63 (0.59-0.68), which was similar to that for age and sex. Combining the PRS with CRFs led to a CRF+PRS model with area under the curve of 0.75 (0.71-0.79), which was 0.04 more than the CRF model ( Adding a PRS improved risk stratification of obstructive CAD beyond CRFs, suggesting a modest clinical potential of using PRSs to guide diagnostic testing in the contemporary clinical setting. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02264717.

Sections du résumé

BACKGROUND
Polygenic risk scores (PRSs) are associated with coronary artery disease (CAD), but the clinical potential of using PRSs at the single-patient level for risk stratification has yet to be established. We investigated whether adding a PRS to clinical risk factors (CRFs) improves risk stratification in patients referred to coronary computed tomography angiography on a suspicion of obstructive CAD.
METHODS
In this prespecified diagnostic substudy of the Dan-NICAD trial (Danish study of Non-Invasive testing in Coronary Artery Disease), we included 1617 consecutive patients with stable chest symptoms and no history of CAD referred for coronary computed tomography angiography. CRFs used for risk stratification were age, sex, symptoms, prior or active smoking, antihypertensive treatment, lipid-lowering treatment, and diabetes. In addition, patients were genotyped, and their PRSs were calculated. All patients underwent coronary computed tomography angiography. Patients with a suspected ≥50% stenosis also underwent invasive coronary angiography with fractional flow reserve. A combined end point of obstructive CAD was defined as a visual invasive coronary angiography stenosis >90%, fractional flow reserve <0.80, or a quantitative coronary analysis stenosis >50% if fractional flow reserve measurements were not feasible.
RESULTS
The PRS was associated with obstructive CAD independent of CRFs (adjusted odds ratio, 1.8 [95% CI, 1.5-2.2] per SD). The PRS had an area under the curve of 0.63 (0.59-0.68), which was similar to that for age and sex. Combining the PRS with CRFs led to a CRF+PRS model with area under the curve of 0.75 (0.71-0.79), which was 0.04 more than the CRF model (
CONCLUSIONS
Adding a PRS improved risk stratification of obstructive CAD beyond CRFs, suggesting a modest clinical potential of using PRSs to guide diagnostic testing in the contemporary clinical setting. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02264717.

Identifiants

pubmed: 34032468
doi: 10.1161/CIRCGEN.120.003298
doi:

Banques de données

ClinicalTrials.gov
['NCT02264717']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e003298

Auteurs

Morten Krogh Christiansen (MK)

Department of Cardiology (M.K.C., J.W., N.R.H., H.K.J., E.H.C., H.E.B.), Aarhus University Hospital, Denmark.
Department of Internal Medicine, Horsens Regional Hospital, Denmark (M.K.C.).

Simon Winther (S)

Department of Cardiology (S.W., M.B.), Hospital Unit West, Herning, Denmark.

Louise Nissen (L)

Department of Radiology (L.N.), Hospital Unit West, Herning, Denmark.

Bjarni Jóhann Vilhjálmsson (BJ)

The National Centre for Register-Based Research (B.J.V.).

Lars Frost (L)

Department of Cardiology, Silkeborg Regional Hospital, Denmark (L.F., J.K.J.).

Jane Kirk Johansen (JK)

Department of Cardiology, Silkeborg Regional Hospital, Denmark (L.F., J.K.J.).

Peter Loof Møller (PL)

Department of Biomedicine (P.L.M., M.N.), Aarhus University, Denmark.

Samuel Emil Schmidt (SE)

Department of Health Science and Technology, Aalborg University, Denmark (S.E.S., M.N.).

Jelmer Westra (J)

Department of Cardiology (M.K.C., J.W., N.R.H., H.K.J., E.H.C., H.E.B.), Aarhus University Hospital, Denmark.

Niels Ramsing Holm (NR)

Department of Cardiology (M.K.C., J.W., N.R.H., H.K.J., E.H.C., H.E.B.), Aarhus University Hospital, Denmark.

Henrik Kjærulf Jensen (HK)

Department of Cardiology (M.K.C., J.W., N.R.H., H.K.J., E.H.C., H.E.B.), Aarhus University Hospital, Denmark.
Department of Clinical Medicine, Faculty of Health (H.K.J., H.E.B.), Aarhus University, Denmark.

Evald Høj Christiansen (EH)

Department of Cardiology (M.K.C., J.W., N.R.H., H.K.J., E.H.C., H.E.B.), Aarhus University Hospital, Denmark.

Daníel Fannar Guðbjartsson (DF)

deCODE Genetics/Amgen, Inc, Reykjavik, Iceland (D.F.G., H.H., K.S.).

Hilma Hólm (H)

deCODE Genetics/Amgen, Inc, Reykjavik, Iceland (D.F.G., H.H., K.S.).

Kári Stefánsson (K)

deCODE Genetics/Amgen, Inc, Reykjavik, Iceland (D.F.G., H.H., K.S.).

Hans Erik Bøtker (HE)

Department of Cardiology (M.K.C., J.W., N.R.H., H.K.J., E.H.C., H.E.B.), Aarhus University Hospital, Denmark.
Department of Clinical Medicine, Faculty of Health (H.K.J., H.E.B.), Aarhus University, Denmark.

Morten Bøttcher (M)

Department of Cardiology (S.W., M.B.), Hospital Unit West, Herning, Denmark.

Mette Nyegaard (M)

Department of Clinical Genetics (M.N.), Aarhus University Hospital, Denmark.
Department of Biomedicine (P.L.M., M.N.), Aarhus University, Denmark.
Department of Health Science and Technology, Aalborg University, Denmark (S.E.S., M.N.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH